- Datum25.09.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Shattuck Labs Inc. Registered Shares DL -,0001
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Shattuck Labs Inc. Registered Shares DL -,0001 Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,64 %
Intraday
0,54 %
1 Woche
6,30 %
1 Monat
-47,97 %
Seit Jahresbeginn
99,46 %
1 Jahr
-80,43 %
3 Jahre
Wikifolio
Passender Service zu Shattuck Labs Inc. Registered Shares DL -,0001
Webinar zu Shattuck Labs Inc. Registered Shares DL -,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,330-11,760
- Jahrestief / Hoch ($)2,870-11,760
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Shattuck Labs Inc. Registered Shares DL -,0001
Keine Dividenden verfügbar
Termine von Shattuck Labs Inc. Registered Shares DL -,0001
Keine aktuellen Termine
Beschreibung
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
